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the IPSS score was respectively 14.3 (6.6) and 11.9 (5.7)
upon patient inclusion and after 6 months. The noted 
difference is statistically signiﬁcant (p < 0.0001). CON-
CLUSION: Patients suffering from a recently diagnosed
BPH and treated with Serenoa Repens thus showed a sta-
tistically signiﬁcant improvement as demonstrated by the
IPSS score.
PRK12
APPLYING CONJOINT ANALYSIS TO THE
VALUATION OF OVERACTIVE BLADDER DRUG-
EFFICACY VARIABLES AND SIDE EFFECTS
Brown MCJ1, Rohr C2, Sheldon R3
1Pﬁzer Limited, Sandwich, Kent, United Kingdom; 2RAND
Europe, Cambridge, United Kingdom; 3Accent Marketing &
Research, Chiswick, London, United Kingdom
OBJECTIVES: The objective of this study was to use con-
joint analysis (CA) to measure patients’ valuations of the
characteristics of drugs used to treat overactive bladder
(OAB) in monetary terms. METHODS: A CA survey
using a discrete choice method was administered in inter-
views with OAB patients in three clinics in the UK
between July 1999 and April 2000. The survey consisted
of a series of pairs of hypothetical OAB drug proﬁles
described in terms of treatment attributes with varying
levels. For each pair the patients were asked to select the
drug proﬁle they preferred. The drug proﬁles included
efﬁcacy attributes (e.g. reduction in urinary incontinence)
and side-effect attributes (e.g. incidence of dry mouth). A
cost attribute was included to allow the calculation of
patients’ valuations of the different attributes in mone-
tary terms. RESULTS: One thousand ﬁve hundred 
twenty discrete choice comparisons of hypothetical OAB
drug treatments were obtained from 95 patients. Based
on these responses, a logit model was estimated that
attempted to explain the reasons why the respondents
made the choices they did. From this model, it is possi-
ble to derive estimates of the implied willingness-to-pay
(WTP) of patients for improvements in OAB drug efﬁcacy
rates and for the incidence of OAB drug-related side
effects. Improvements in efﬁcacy attributes have positive
WTP estimates (from £2.20 to £11.22 per day) and the
WTP estimates are negative for the incidence of side-effect
attributes (from -£2.79 to -£9.83 per day). CONCLU-
SIONS: This study demonstrates the capability of the CA
technique to measure valuations of varying drug proﬁles
in monetary terms. The results of this study could be used
to estimate the WTP of patients for different OAB drug
treatments.
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OBJECTIVES: Overactive Bladder (OAB) patients with
symptoms of frequency, urgency, and urge incontinence
treated with tolterodine showed signiﬁcant improvement
over placebo on 6 (4mg ER) or seven (2mg IR) of 10
King’s Health Questionnaire (KHQ) domains in a 12-
week randomized, double-blind trial (Phase A). Patients
were permitted to continue in a 12-month open-label
study (Phase B) to assess long-term effects of toltero-
dine ER. Regional differences in treatment effects on
health-related quality of life (HRQoL) were assessed.
METHODS: The KHQ was administered at baseline, end
of Phase A, and after 3 and 12 months in Phase B. An
intent-to-treat population for whom KHQ translations
were available (n = 858) was used in ANCOVA models
with baseline score, age, and gender as covariates. Region
and placebo effects were measured using a model with
treatment, region, and treatment by region as factors.
Long-term effects of tolterodine were assessed using a
split plot, repeated measures model where visits and treat-
ment were factors. RESULTS: Change from baseline to
end of Phase B analysis showed no signiﬁcant differences
in KHQ scores between patients in North America (US =
439, Canada = 67) and the rest of the world (Europe plus
Australia and New Zealand [EU+, n = 332]). Only the
Personal Relationships domain showed evidence of a
region interaction effect. Change from rollover analysis
of a subgroup of U.S. patients (n = 305) showed that
treatment effects persisted (8 domains) or improved (2
domains) after 12 months of additional treatment. These
results are generally consistent with the pooled analysis.
CONCLUSIONS: Treatment with tolterodine improves
HRQoL and improvements observed after initial treat-
ment persist in the longer term. In general, physical 
and symptom domains improved quickly and changes in
social and psychological domains became evident after
longer treatment. There does not appear to be a differ-
ence in these effects by region.
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OBJECTIVES: Performing a basic evaluation of a resi-
dent’s urinary incontinence (UI) condition is needed to
determine the cause of the incontinence and guide appro-
priate treatment. The two objectives of this study were 1)
to determine the prevalence of residents with UI that
received one or more of the four parts of the Agency for
Health Care Policy and Research (AHCPR) basic evalu-
ation guidelines, and 2) to compare the effectiveness of
two types of oral antimuscarinic medications—toltero-
dine and oxybutynin. METHODS: Data were extracted
from medical and Minimum Data Set records in 30
nursing homes in 5 regions of Texas. RESULTS: For
Objective 1, medical charts of 255 residents were
reviewed. There were 64 residents that met the study cri-
teria for Objective 2. Regarding Objective 1, the major-
ity (n = 179, 70.2 percent) had no documentation of any
part of the basic evaluation that is recommended for
patients with urinary incontinence. Fifty-seven patients
(22.3 percent) had documentation of one part of the eval-
uation, while less than 8% (n = 19) had two or more parts
of the basic evaluation documented. Female residents
were more likely than male residents to have one or more
parts of the basic evaluation performed. Residents resid-
ing in nursing homes located in urban areas were more
likely to have one or more parts of the basic evaluation
performed compared to residents residing in rural setting
nursing homes. For Objective 2, results showed that 
residents receiving tolterodine had a greater decrease in
urinary incontinence severity levels than residents receiv-
ing oxybutynin. Female residents had a greater improve-
ment in UI levels than male residents. CONCLUSIONS:
The sparse documentation of basic urinary incontinence
evaluations indicates that health care providers and deci-
sion makers need to continue to focus on ways to improve
the evaluation and management of urinary incontinence
in elderly nursing home residents.
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OBJECTIVES: To identify the range of clinical manage-
ment strategies used to reduce CMV infection and disease
following renal transplantation in France. METHODS: A
questionnaire-based survey tool was developed over a
three-month period, with review provided by an expert
committee consisting of three clinicians and a leading
health economist. The ﬁnalised questionnaire was sent
out to the 35 centres for adults existing throughout
France. The questionnaire requested information on the
number of transplanted patients, the proportions of
patients in recognised CMV risk groups based on donor
and recipient CMV status, the types of risk reduction
strategies adopted, the treatment protocols for CMV
disease and ﬁnally the incidence of CMV disease by risk
group. Respondents were asked to use actual data records
wherever possible. RESULTS: Overall 31 centres com-
pleted the survey, a response rate of 89%. The centres
performed 1641 adult transplantations during the year
2000. The average number of patients per centre was 53,
ranging between 20 to 140 per year. Around 25% of
patients were considered at low-risk of CMV (D-R-),
50% were R+ and 30% were D+R-. However, the dis-
tribution of patients varied greatly across centres. The
most commonly adopted strategy in the D+R- group 
was prophylaxis using oral valaciclovir. In the remaining
patients most centres used close monitoring with pre-
emptive drug treatment using oral ganciclovir or valaci-
clovir. Altogether, there were around 250 cases of CMV,
approximately 30% being tissue invasive disease and
70% general symptoms only. CONCLUSION: The
survey conﬁrms the wide variation of patient types across
centres in France. The CMV incidence results also
conﬁrm the increased risk faced by the D+R- patient
group, which may be enhanced further through the wide-
spread use of antilymphocyte therapy. Although pro-
phylaxis treatment appears widely used in higher–risk
patients, around 20% of centres currently wait until 
the presentation of CMV symptoms before initiating
treatment.
WOMEN’S AND MEN’S HEALTH—Economic
Outcomes
PWM1
HEALTH CARE RESOURCE USE FOR HEAVY
MENSTRUAL LOSS
Jacobs P1, Cumming D1, Cote I2
1University of Alberta, Edmonton, AB, Canada; 2Bayer Inc,
Toronto, ON, Canada
OBJECTIVES: Heavy menstrual bleeding is experienced
by a large number (approx. 13%) of women and precip-
itates considerable use of health care. We estimate the use
of resources for women with increased bleeding, using a
population health survey. METHODS: The database used
is the 1999 United States National Health Interview
Survey (NHIS). The study population is all women age
18 and above. The dependent variables are categorical,
indicating whether or not women used a series of health
care services. The independent variables comprise the
study variable (indicating increased menstrual ﬂow) 
and demographic and socioeconomic variables. Logistic
regressions were run for each type of service. RESULTS:
In the sample of 2805 women, 373 (13.3 per cent) 
women had increased menstrual ﬂow. The odds ratio,
indicating the net impact of increased ﬂow was estimated
for the following services (* indicates signiﬁcant at .05
level): general practitioners, 1.48*; emergency room,
